2024-11-26 - Analysis Report
## Teladoc Health Inc. (TDOC) Stock Report

**1. Performance Comparison & Divergence:**

Teladoc Health (TDOC) has significantly underperformed the S&P 500 (VOO) over the analyzed period.  The cumulative return for TDOC is -58.45%, while VOO shows a 126.88% return. This results in a substantial divergence of -185.33%, placing it at the 1.08 percentile of its historical range relative to the S&P 500.  (Note: A higher percentile doesn't necessarily imply outperformance; it just indicates its relative position within its historical range of performance vs. the S&P 500).

**Company Overview:** Teladoc Health Inc. is a provider of virtual healthcare services, offering telehealth consultations and related services.

**Alpha and Beta Analysis:** The provided data shows high beta values (generally above 1), indicating high volatility and sensitivity to market movements. Alpha values fluctuate, sometimes positive, sometimes negative, suggesting periods of outperformance and underperformance relative to the market.  The significant negative CAGR in recent years (2020-2024) strongly reflects the underperformance. The high Maximum Drawdown (MDD) figures highlight the substantial risk associated with investing in TDOC.

**2. Recent Price Movement:**

* **Closing Price:** $12.02
* **5-Day Moving Average:** $10.19
* **20-Day Moving Average:** $9.47
* **60-Day Moving Average:** $8.91

The price is above all three moving averages, suggesting a recent upward trend.  The relatively large gap between the current price and the moving averages might indicate a recent surge.

**3. Technical Indicators & Expected Return:**

* **RSI (75.22):**  Indicates the stock is in overbought territory, suggesting potential for a price correction.
* **PPO (2.24):** A positive value suggests bullish momentum, but the high RSI casts doubt on its sustainability.
* **Delta_Previous_Relative_Divergence (0.82+):** Shows a recent positive shift in relative strength against the benchmark. However, this is short-term and needs to be viewed in the context of the overall longer-term underperformance.
* **Expected Return (0.0%):** The provided expected return of 0% suggests that, based on current data, there's no anticipated long-term outperformance relative to the S&P 500.  This is a highly uncertain prediction, given the volatility and recent poor performance. The 0% is a baseline, considering the substantial risk and underperformance compared to the market.


**4. Recent Financial Performance:**

The provided EPS figures show consistent losses throughout the reported periods. While revenue remains relatively stable, the substantial negative EPS raises concerns about profitability.  The most recent EPS of -0.19 needs to be compared against analyst expectations (not provided) to fully assess its performance.

**6. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue is relatively stable, but profit margins, while high, have shown some minor fluctuation.
* **Capital and Profitability:**  The Return on Equity (ROE) is consistently negative, indicating the company is not generating returns for its shareholders. This is a significant concern.  The substantial decrease in equity during Q2 2024 also points to financial weakness.


**7. News and Recent Issues:**

*(This section requires access to real-time news sources like Seeking Alpha, Yahoo Finance, etc. to provide accurate information on recent earnings announcements, analyst opinions, and market outlook for TDOC.  Please provide links to relevant news articles if you have them.)*  I cannot access real-time information.  A thorough analysis requires reviewing recent news coverage from reputable sources.

**8. Overall Analysis:**

TDOC has significantly underperformed the S&P 500, showing consistent losses and negative ROE. While recent price action suggests a short-term upward trend, this is happening in the context of long-term underperformance and high volatility.  Overbought conditions (high RSI) suggest potential for a pullback.  The company's profitability is a serious concern.  Further investigation of recent news, analyst ratings, and earnings calls is crucial before making any investment decision. The 0% expected return should be interpreted cautiously as a baseline, given the risk and the substantial underperformance to date.

**9. English Report Summary:**

Teladoc Health (TDOC) exhibits significant underperformance against the S&P 500, reflected in a substantial negative cumulative return.  High volatility, negative ROE, and consistent losses raise significant concerns about profitability and long-term sustainability.  While recent price increases show short-term momentum above moving averages, overbought conditions (high RSI) suggest a potential correction.  Analysis of recent news and analyst opinions is critical before investing.  The 0% expected return relative to the S&P 500 represents a highly uncertain baseline in light of the company's financial performance and market volatility.  Further due diligence is strongly recommended.
